Invictus Announces New Go Forward Leadership Team
Vancouver, BC / TheNewswire / November 5, 2018 – INVICTUS MD STRATEGIES CORP. (“Invictus” or the “Company”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) announced today the resignation of Dan Kriznic as CEO and Chairman of the Company, effective immediately. Kriznic will remain with the Company as an advisor to the new Chairman and CEO. Kriznic commented “I co-founded Invictus in 2014 with the vision of creating a global cannabis company. To date, we have raised over $125 million and deployed capital into the acquisition of licenses and the construction of advanced commercial cultivation facilities.” He added “The next chapter will be focused on operations with a disciplined multi-distribution and brand approach to the Canadian and international markets. The leadership team has been built out and ready to deploy the vision. I want to thank all of our shareholders and our directors for the many years of support and look forward to what the future brings for the Company and its stakeholders.”
Paul Sparkes, non-executive Director since 2017, has been nominated and unanimously approved by the Board to act as Chairman of the Board. Sparkes is an accomplished business executive and entrepreneur with more than 25 years of experience in media, advisory, finance, public affairs and politics. He is currently a director of Thunderbird Entertainment (TSXV: TBRD) and was previously a director of the Liquor Control Board of Ontario. Sparkes held senior positions in public service, including with the Government of Canada, as Director of Operations to the Prime Minister of Canada.
George E. Kveton, advisor and non-executive Director since 2015, has been nominated and unanimously approved by the Board to be the new CEO, effective immediately. Kveton is a longstanding, seasoned international executive with broad operating experience in regulated fast-moving consumer goods industries (“FMCG”), including big tobacco. His leadership, coupled with a strong financial and strategic acumen, will serve the Company well as it embarks upon its next important chapter of growth to become a leading medical and recreational cannabis Company.
Kveton has spent over two decades leading transformational M&A for Philip Morris International and Japan Tobacco International, both headquartered in Switzerland. His multi-billion dollar deal sheet is global and spans start-ups in Silicon Valley, Israel and China, to large private and public companies. Kveton has extensive experience in emerging markets, regulatory policy and the transformation of acquired businesses to realize market share and gains. Kveton began his career as a tax and business advisory consultant for Arthur Andersen in Prague, Czech Republic, and has held various positions of increased responsibility including Head of Business Development and Planning, and Global Strategy. Kveton, Canadian-born and Swiss national, is a graduate of Queen’s University in Canada, and executive programs at UC Berkeley Haas School of Business and Harvard Business School.
It’s with great pleasure that I take on the role as CEO of the Company. I have been a Director and shareholder since the beginning, and have watched and assisted the Company to diligently action upon its growth strategy. The foundation of Invictus is strong and poised for growth now that Canada is both recreational and medically legal.
George Kveton, CEO
Leveraging upon my global network and FMGC experience, the Company will not only strive to become a major cannabis player in Canada, but also abroad. I am fortunate to be leading an agile executive team with the pedigree and passion that will allow the Company to achieve its strategic objectives.
At the same time, Invictus announces that it has enlisted a Toronto-based full-service strategic consulting agency (“StratCo”) to execute the Company’s portfolio and brand awareness strategy. Effective immediately, this appointment reinforces Invictus’ bench strength in the sales and marketing area. StratCo will develop and execute a brand awareness strategy for both recreational and medical cannabis. Its President and Chief Strategist is a passionate communicator and problem solver with 35 years in the pharmaceutical industry; both on the corporate side and through consulting, working with some of the most successful biotech and pharma start-ups and giants alike.
Invictus has also granted 750,000 incentive stock options to a certain eligible person of the Company. Each stock option has an exercise price of $2.00, the equivalent price paid per Unit in connection with the Company’s recent short form prospectus (see press release dated October 19, 2018, for more details), and is exercisable into one common share of the Company. The options vest in tranches over the next eighteen (18) months and are exercisable over a period of five years. The stock options were granted subject to the terms and conditions of the Company’s Stock Option Plan.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
George E. Kveton
CEO and Director
Vice President, Public Relations and Regulatory Affairs
Invictus is a global cannabis company offering a selection of products under a wide range of brands. Our integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores.
Invictus has partnered with business leaders to convey our corporate vision, including KISS music legend and business mogul Gene Simmons as our Chief Evangelist Officer. To meet growing demand, Invictus is expanding its cultivation footprint, with two cannabis production facilities fully licensed under ACMPR in Canada and a third awaiting approval of its sales license, featuring 100,000 square feet of available grow space today with 200,000 expected by January 2019 and up to 1 million by end of 2020. To accommodate international sales, Invictus’ wholly-owned subsidiary, Acreage Pharms Ltd. (“Acreage Pharms”), has designed and is currently building its Phase 3 and 4 purpose-built cultivation facilities to be European Union Good Manufacturing Practices (“EU-GMP”) compliant. The Company will earmark up to 50 per cent of production to medical use cannabis. To ensure consistency in quality and supply, Invictus maintains all aspects of the growing process through its subsidiary, Future Harvest Development Ltd., a high-quality Fertilizer and Nutrients manufacturer. Invictus drives sustainable long-term shareholder value through a diversified product portfolio with over 69 Health Canada approved strains and a multifaceted distribution strategy including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores. For more information visit www.invictus-md.com.
Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.